Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN D versus CLISTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN D versus CLISTIN.
CLARITIN-D vs CLISTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
Clistin (histamine-1 receptor antagonist) competitively blocks histamine at H1 receptor sites, inhibiting vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
4 mg orally every 4-6 hours as needed; maximum 24 mg/day.
None Documented
None Documented
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Primarily renal excretion (approximately 85-90% as unchanged drug and metabolites). Biliary/fecal elimination accounts for the remainder (10-15%).
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine